Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mFOLFOXIRI Plus Bevacizumab vs FOLFOX Followed by CRT in Rectal Cancer
NCT04215731Phase 3Recruiting
- Sponsor
- Yanhong Deng
- Start
- Mar 2020
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of bevacizumab, folinic acid + 5-fluorouracil + oxaliplatin + irinotecan in rectal cancer, sponsored by Yanhong Deng. Started Mar 2020; status: recruiting.
02
Drugs
bevacizumabfolinic acid + 5-fluorouracil + oxaliplatin + irinotecan
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT04215731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04215731.